Eisai Announces Launch of Vascular Embolization Device DC Bead(R) in Japan
Tokyo, Feb 3, 2014 – (JCN Newswire) – Eisai Co., Ltd. announced today that it will launch the vascular embolization device DC Bead(R) (specially controlled medical device) in Japan on February 4.
DC Bead contains hydrophilic microspheres made from cross-linked polyvinyl alcohol polymer. Developed by Biocompatibles UK Limited (Biocompatibles), a BTG International group company, as an intravascular embolization device, it is injected via catheter into targeted blood vessels to achieve selective embolization. DC Bead is already marketed as an effective embolization device in the treatment of hepatocellular carcinoma (HCC) and other hypervascularized tumors in more than 50 countries and territories worldwide, including in Europe and the United States.
Eisai acquired the exclusive rights to develop and market DC Bead in Japan from Biocompatibles in July 2009 and received manufacturing and marketing authorization for the device from Japan’s Ministry of Health, Labour and Welfare in April 2013 for use in transcatheter arterial embolization (TAE) in patients with HCC. On February 1, 2014, DC Bead was classified in the Special Treatment Materials (STM) category for medical device reimbursement under the country’s National Health Insurance system.
In Japan, the Eisai Group markets a diverse range of medical devices and pharmaceuticals for the diagnosis and treatment of liver diseases. These products include the non-ionic contrast medium Iomeron(R) and non-ionic contrast medium for MRI ProHance(R), both of which are imaging devices used in HCC diagnosis, the in-vitro diagnostic tool PIVKA-II Kit, which is used to measure the HCC marker PIVKA-II/DCP, and two liver disease medications and anti-allergy agents, Stronger Neo-Minophagen(R) C and Glycyron(R) Tablets. Through the launch of DC Bead in Japan, Eisai seeks to further enhance its liver disease product portfolio in the country as well as continue to contribute to addressing the diverse needs of, and increasing the benefits provided to, patients with HCC and their families.
About DC Bead
DC Bead contains hydrophilic microspheres (beads) produced made from cross-linked polyvinyl alcohol polymer. As a vascular embolization device, it is injected via catheter into targeted blood vessels to achieve selective embolization. Due to the beads being both microscopic and uniformly spherical, DC Bead allows for sustained embolization of targeted blood vessels based on vascular diameter and tumor size, with each embolization procedure confirmed through endoscopic observation of the targeted vessels. Following its launch in Japan, the device will be domestically available in three bead sizes (100-300 micro-m, 300-500 micro-m, and 500-700 micro-m) so that an appropriate bead size can be selected based on vascular diameter, tumor size and extent of intended embolization in the targeted blood vessel.
In addition to DC Bead’s indication in Japan for transcatheter arterial embolization (TAE) therapy in patients with hepatocellular carcinoma (HCC), Eisai is currently conducting Phase III clinical trials of DC Bead in Japan as an effective embolization device for treating other hypervascularized tumors.
Hypervascularized tumors most commonly refer to hepatocellular carcinoma (HCC), renal cell carcinoma, bone and soft tissue sarcoma, and other tumors that receive nourishment via a sophisticated vascular network formed in tumor tissue.
About Transcatheter Arterial Embolization (TAE)
TAE is a therapy that selectively obstructs blood circulation to induce necrosis in hepatocellular carcinoma (HCC) by injecting embolization material into the hepatic artery, the artery that supplies nutrient blood to the tumor. In contrast to healthy liver cells, which receive blood from both the hepatic artery and portal vein, HCC cells receive blood mainly from the hepatic artery via a vascular network formed in the tumor tissue.
Consequently, by using embolizing material to selectively embolize blood vessels in the hepatic artery, selective necrosis can be more effectively induced at the tumor site. There are two types of TAE therapy: one involving embolization without chemotherapy, and transcatheter arterial chemo-embolization (TACE), the latter of which is performed in combination with chemotherapeutic agents to suppress cancer cell activity.
Eisai Co., Ltd. (TSE: 4523; ADR: ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.com.
Public Relations Department,
Eisai Co., Ltd.
Copyright 2014 JCN Newswire. All rights reserved. www.japancorp.net